Prepare for future prostate cancer treatment

The PINgenius™ Test allows patients to prepare for the future by knowing their risk. Developed by our pathology laboratory services team at Inform Diagnostics, this new test helps treating physicians predict the risk of prostate cancer at re-biopsy for patients with high-grade prostatic intraepithelial neoplasia (HGPIN).

The results of the PINgenius™ Test allow medical professionals to answer questions such as:

  • Which HGPIN patients need re-biopsy?
  • Which HGPIN patients need conservative follow-up?

About the PINgenius™ Test

Predict the risk of prostate cancer at re-biopsy

Inform Diagnostics independent research suggests a high-risk (~60%) of discovering prostate cancer upon re-biopsy when testing positive for PINgenius, combined with certain histological risk factors:

  • High-grade prostatic intraepithelial neoplasia (HGPIN) is a putative precursor lesion to prostate cancer.
  • Men with an isolated HGPIN diagnosis from a prostate biopsy are at risk of harboring or developing prostate cancer at repeat biopsy.
  • Existing clinical and pathological risk-assessment tools have not accurately and consistently identified which patients should be conservatively followed and which patients will need a repeat biopsy.
  • The PINgenius™ Test employs biomarker overexpression as well as several histological factors to help gauge the risk of prostate cancer at repeat biopsy.

Recommendations

Giving clinicians confidence to recommend next steps

The following are recommendations based on various PINgenius results:

  • If PINgenius result suggests HIGH RISK—Repeat biopsy may be indicated.
  • If PINgenius result suggests LOW RISK—Conservative follow up may be indicated; delay or avoid re-biopsy unless other clinical parameters require re-biopsy.

NOTE: The timeframe to schedule re-biopsy is a decision made between the clinician and patient.

Questions?

Learn more about the PINgenius™ Test

Please contact us with your questions about the PINgenius™ Test. We can connect you to a member of our Sales or Pathology teams.

Additional recommended reading:

  • Shah RB, Li J, Dhanani N, Mendrinos S. ERG overexpression and multifocality predict prostate cancer in subsequent biopsy for patients with high-grade prostatic intraepithelial neoplasia. Urol Oncol. 2015; 34(3): 120.e1-7
  • Park K et al. TMPRSS2: ERG Gene Fusion Predicts Subsequent Detection of Prostate Cancer in Patients with High-grade Prostatic Intraepithelial Neoplasia. Journal of Clin Oncology, 2013
  • Shah RB. Clinical Application of Novel ERG immunohistochemistry in Prostate Cancer Diagnosis and Management. Review. Adv Anat Pathol, 20(2): 117–24, 2013
  • Furusato B, Tan SH, Young D, et al. ERG oncoprotein expression in prostate cancer: clonal progression of ERG-positive tumor cells and potential for ERG-based stratification. Prostate Cancer Prostatic Dis 2010; 13: 228–37.